<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000644304">
  <TermName>cixutumumab</TermName>
  <TermPronunciation>(SIK-syoo-TOO-myoo-mab)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of some types of cancer. It is a monoclonal antibody that is made in the laboratory and can bind to substances in the body. Cixutumumab blocks the action of a protein needed for cell growth and may kill cancer cells. It is a type of insulin-like growth factor-1 receptor (IGF-1R) inhibitor. Also called IMC-A12.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000726057" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;cixutumumab&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000726056" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;cixutumumab&quot;" language="es" id="_4"/>
  <SpanishTermName>cixutumumab</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de algunos tipos de cáncer. Es un anticuerpo monoclonal que se produce en el laboratorio y se puede unir a sustancias del cuerpo. El cixutumumab impide la acción de una proteína que las células necesitan para crecer y podría destruir células cancerosas. Es un tipo de inhibidor del receptor del factor de crecimiento similar a la insulina  I (IGFR-I). También se llama IMC-A12.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateFirstPublished>2009-10-05</DateFirstPublished>
</GlossaryTerm>
